148 related articles for article (PubMed ID: 28174164)
1. Improving malodour management in advanced cancer: a 10-year retrospective study of topical, oral and maintenance metronidazole.
George R; Prasoona TS; Kandasamy R; Cherian R; Celine T; Jeba J; Murali S; Mathew D
BMJ Support Palliat Care; 2017 Sep; 7(3):286-291. PubMed ID: 28174164
[TBL] [Abstract][Full Text] [Related]
2. The management of malodour and exudate in fungating wounds.
Draper C
Br J Nurs; 2005 Jun 9-22; 14(11):S4-12. PubMed ID: 15976610
[TBL] [Abstract][Full Text] [Related]
3. The effect of topical 0.75% metronidazole gel on malodorous cutaneous ulcers.
Finlay IG; Bowszyc J; Ramlau C; Gwiezdzinski Z
J Pain Symptom Manage; 1996 Mar; 11(3):158-62. PubMed ID: 8851373
[TBL] [Abstract][Full Text] [Related]
4. A topical metronidazole gel used to treat malodorous wounds.
Bale S; Tebbie N; Price P
Br J Nurs; 2004 Jun; 13(11):S4-11. PubMed ID: 15218439
[TBL] [Abstract][Full Text] [Related]
5. Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0.75 % gel (GK567): a multicenter, open-label, phase III study (RDT.07.SRE.27013).
Watanabe K; Shimo A; Tsugawa K; Tokuda Y; Yamauchi H; Miyai E; Takemura K; Ikoma A; Nakamura S
Support Care Cancer; 2016 Jun; 24(6):2583-90. PubMed ID: 26715293
[TBL] [Abstract][Full Text] [Related]
6. Topical metronidazole for the treatment of wound odor: a review of the literature.
Paul JC; Pieper BA
Ostomy Wound Manage; 2008 Mar; 54(3):18-27; quiz 28-9. PubMed ID: 18382045
[TBL] [Abstract][Full Text] [Related]
7. Malodour from oral malignant fungating wound: sprayed metronidazole - case report.
Harano H; Matsunuma R; Tanaka-Yagi Y; Ito M; Tasaki J; Egawa A; Yamaguchi T
BMJ Support Palliat Care; 2024 Jan; 13(e3):e966-e967. PubMed ID: 36944483
[TBL] [Abstract][Full Text] [Related]
8. Regular Low-Dose Oral Metronidazole Is Associated With Fewer Vesicovaginal and Rectovaginal Fistulae in Recurrent Cervical Cancer: Results From a 10-Year Retrospective Cohort.
George R; Prasoona TS; Kandasamy R; Mani T; Murali S; Rekha R; Muliyil J
J Glob Oncol; 2019 Sep; 5():1-10. PubMed ID: 31479340
[TBL] [Abstract][Full Text] [Related]
9. Topical Metronidazole for Odor Control in Pressure Ulcers.
Lyvers E; Elliott DP
Consult Pharm; 2015 Sep; 30(9):523-6. PubMed ID: 26350892
[TBL] [Abstract][Full Text] [Related]
10. Metrotop: a topical antimicrobial agent for malodorous wounds.
Moody M
Br J Nurs; 1998 Mar 12-25; 7(5):286-9. PubMed ID: 9616550
[TBL] [Abstract][Full Text] [Related]
11. A palliative approach to the management of malodour from malignant fungating tumours.
West D
Int J Palliat Nurs; 2007 Mar; 13(3):137-42. PubMed ID: 17505407
[TBL] [Abstract][Full Text] [Related]
12. Malignant fungating wounds: managing malodour and exudate.
Alexander S
J Wound Care; 2009 Sep; 18(9):374-82. PubMed ID: 19789474
[TBL] [Abstract][Full Text] [Related]
13. An update on the role of topical metronidazole in rosacea.
Zip C
Skin Therapy Lett; 2006 Mar; 11(2):1-4. PubMed ID: 16598386
[TBL] [Abstract][Full Text] [Related]
14. Use of metronidazole gel to control malodor in advanced and recurrent breast cancer.
Kuge S; Tokuda Y; Ohta M; Okumura A; Kubota M; Ninomiya S; Sawamura S; Makuuchi H; Tajima T; Mitomi T
Jpn J Clin Oncol; 1996 Aug; 26(4):207-10. PubMed ID: 8765176
[TBL] [Abstract][Full Text] [Related]
15. The role of topical metronidazole in the treatment of rosacea.
Wolf JE
Cutis; 2004 Jan; 73(1 Suppl):19-28. PubMed ID: 14959942
[TBL] [Abstract][Full Text] [Related]
16. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea.
Wolf JE; Del Rosso JQ
Cutis; 2007 Jan; 79(1):73-80. PubMed ID: 17330626
[TBL] [Abstract][Full Text] [Related]
17. [Metronidazole: alternative treatment for ocular and cutaneous rosacea in the pediatric population].
Léoni S; Mesplié N; Aitali F; Chamaillard M; Boralevi F; Marques da Costa C; Taïeb A; Léauté-Labrèze C; Colin J; Mortemousque B
J Fr Ophtalmol; 2011 Dec; 34(10):703-10. PubMed ID: 21885154
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.
Del Rosso JQ
Cutis; 2010 Nov; 86(5 Suppl):16-25. PubMed ID: 21229827
[TBL] [Abstract][Full Text] [Related]
19. Metronidazole gel in managing malodorous fungating wounds.
Clark J
Br J Nurs; 2002 Mar; 11(6 Suppl):S54-60. PubMed ID: 11979191
[TBL] [Abstract][Full Text] [Related]
20. Innovative use of topical metronidazole.
Zip CM
Dermatol Clin; 2010 Jul; 28(3):525-34. PubMed ID: 20510762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
